340B Entities Will Continue Fighting For Inpatient Drug Discounts
Executive Summary
Extending what are known as 340B drug discounts to include inpatient drugs as well as outpatient products is one of the top legislative priorities for the Safety Net Hospitals for Pharmaceutical Access
You may also be interested in...
340B Price Setting Policy Should Precede Dispute, Penalty Actions, BIO Urges
The Health Resources and Services Administration should publish standards and methods for calculating “ceiling” prices under the 340B drug discount program before activating new processes for settling purchasing disputes between drug firms and institutions or fining non-compliant drug companies, the Biotechnology Industry Organization urges in recent comments to the agency.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011